Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PPIB | P23284 | 1/20 | 0.33 |
| ▸ | PPIA | P62937 | 1/20 | 0.33 |
| ▸ | PPID | Q08752 | 1/20 | 0.33 |
| ▸ | PPIG | Q13427 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064713 | 1.00 | ACHE (0.39) | ACHEMEN1KMT2AGAACHRNB2 | |
| SCHEMBL1064714 | 0.84 | ACHE (0.42) | ACHEMEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL1065642 | 0.84 | ACHE (0.42) | ACHEMEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL3364343 | 0.83 | TLR2 (0.35) | ACHEMEN1KMT2AGAACHRNB2 | |
| SCHEMBL1064998 | 0.80 | ACHE (0.41) | ACHEMEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL1061879 | 0.80 | ACHE (0.41) | ACHEMEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL3361834 | 0.80 | ACHE (0.41) | ACHEMEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL20469924 | 0.76 | ACHE (0.46) | ACHEMEN1KMT2ACHRNB2CHRNB4 | |
| SCHEMBL18685483 | 0.73 | TDP1 (0.39) | GAALMNA | |
| SCHEMBL11141024 | 0.72 | ACHE (0.52) | ACHEMEN1KMT2AL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450469-B2 | Synthesis of peptide nucleic acids conjugated with amino acids and their application | PANAGENE INC. (KR) | 2013-05-28 | — | — | US | disclosed |
| US-20110014715-A1 | Synthesis of Peptide Nucleic Acids Conjugated with Amino Acids and Their Application | PANAGENE INC. (KR) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014715-A1 | Synthesis of Peptide Nucleic Acids Conjugated with Amino Acids and Their Application | CPSF6, RNGTT, DNPEP | ACHE 4498/4885MEN1 4198/4885KMT2A 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.